Overexpressed miR-155 is associated with initial presentation and poor outcome in Chinese pediatric acute myeloid leukemia

被引:0
|
作者
Xu, L. -H. [1 ,2 ]
Guo, Y. [2 ]
Cen, J. -N. [3 ]
Yan, W. -Y. [4 ]
He, H. -L. [1 ]
Niu, Y. -N. [5 ]
Lin, Y. -X. [4 ]
Chen, C. -S. [6 ,7 ]
Hu, S. -Y. [1 ]
机构
[1] Soochow Univ, Childrens Hosp, Dept Hematol & Oncol, Suzhou, Jiangsu, Peoples R China
[2] First Peoples Hosp Lianyungang, Lianyungang, Jiangsu, Peoples R China
[3] Soochow Univ, Affiliated Hosp 1, Suzhou, Jiangsu, Peoples R China
[4] Soochow Univ, Ctr Syst Biol, Suzhou, Jiangsu, Peoples R China
[5] Xinxiang Med Univ, Sch Lab Med, Xinxiang, Henan, Peoples R China
[6] Loma Linda Univ, Div Hematol & Med Oncol, Dept Internal Med, Loma Linda, CA 92350 USA
[7] Loma Linda Univ, Biospecimen Lab, Loma Linda, CA 92350 USA
基金
中国国家自然科学基金;
关键词
MiR-155; MiR-25; Pediatric acute myeloid leukemia; Diagnosis; Prognosis; ACUTE LYMPHOBLASTIC-LEUKEMIA; INTERNAL TANDEM DUPLICATION; MICRORNA EXPRESSION; KIT MUTATIONS; AML; IDENTIFICATION; SIGNATURES; PROGNOSIS; CANCER; CELLS;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: Acute myeloid leukemia (AML) is the second leading leukemia in children. There is growing evidence that microRNAs (miRNAs) are crucial regulators involved in leukemogenesis. This study aimed to investigate the role of miR-155 in Chinese pediatric AML by evaluating its diagnostic and prognostic significance. PATIENTS AND METHODS: The expression of miR-155 and miR-25 in bone marrow specimens from 83 AML and 29 non-malignancies children were analyzed by TaqMan probe-based real-time quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR). RESULTS: The expression level of miR-155 was significantly higher in AML patients than in controls. Besides, a lowest miR-155 level was found in favorable prognosis group and t (15; 17)/M3 subgroup compared to the rest, while a higher level in C-Kit/FLT3-ITD mutation and relatively lower level existed in "Negative" mutation group. Moreover, miR-155 level was positively associated with the white blood cell (WBC) count, serum lactate dehydrogenase (LDH) and C-reaction protein (CRP) value in peripheral blood (PB), as well as miR-25/miR-196b expression levels. Survival analysis showed a statistically negative association with overall survival (OS) in the expression of miR-155 in chemotherapy group. CONCLUSIONS: These finding suggested that miR-155 expression cannot only be promising biomarker for the early detection of pediatric AML but also predict poor outcome. MiR-155 would be a novel biomarker for diagnosis, prognosis and therapy in pediatric AML.
引用
收藏
页码:4841 / 4850
页数:10
相关论文
共 50 条
  • [41] Pediatric Acute Myeloid Leukemia: How to Improve Outcome?
    Szalontay L.
    Shad A.T.
    Current Pediatrics Reports, 2014, 2 (1) : 26 - 37
  • [42] Rare Initial Presentation of Acute Myeloid Leukemia as Facial Palsy
    Budhiraja, Shilpi
    Sagar, Prem
    Rajeshwari, Madhu
    Kumar, Rajeev
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2018, 39 (04) : 555 - 557
  • [43] Pleural Effusion as an Unusual Initial Presentation of Acute Myeloid Leukemia
    Agarwal, Mukul
    Purohit, Abhishek H. L.
    Mahapatra, Manoranjan
    Kumar, Rajeev
    Mishra, Pravas
    Seth, Tulika
    Saxena, Renu
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2014, 30 (03) : 195 - 196
  • [44] Major postpartum hemorrhage as an initial presentation of acute myeloid leukemia
    Lee, WL
    Wang, PH
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 1999, 66 (02) : 173 - 174
  • [45] Pleural Effusion as an Unusual Initial Presentation of Acute Myeloid Leukemia
    Mukul Agarwal
    Abhishek HL Purohit
    Manoranjan Mahapatra
    Rajeev Kumar
    Pravas Mishra
    Tulika Seth
    Renu Saxena
    Indian Journal of Hematology and Blood Transfusion, 2014, 30 : 195 - 196
  • [46] Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia
    Alachkar, Houda
    Santhanam, Ramasamy
    Harb, Jason G.
    Lucas, David M.
    Oaks, Joshua J.
    Hickey, Christopher J.
    Pan, Li
    Kinghorn, A. Douglas
    Caligiuri, Michael A.
    Perrotti, Danilo
    Byrd, John C.
    Garzon, Ramiro
    Grever, Michael R.
    Marcucci, Guido
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6
  • [47] Low serum miR-223 expression predicts poor outcome in patients with acute myeloid leukemia
    Yu, Guopan
    Yin, Zhao
    He, Han
    Zheng, Zhongxin
    Chai, Yanyan
    Xuan, Li
    Lin, Ren
    Wang, Qiang
    Li, Jie
    Xu, Dan
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2020, 34 (03)
  • [48] Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia
    Houda Alachkar
    Ramasamy Santhanam
    Jason G Harb
    David M Lucas
    Joshua J Oaks
    Christopher J Hickey
    Li Pan
    A Douglas Kinghorn
    Michael A Caligiuri
    Danilo Perrotti
    John C Byrd
    Ramiro Garzon
    Michael R Grever
    Guido Marcucci
    Journal of Hematology & Oncology, 6
  • [49] VEGFC Predicts Poor Outcome in Pediatric as Well as Adult Acute Myeloid Leukemia: Insights in Associated Gene Expression Profiles.
    de Jonge, Hendrik J. M.
    Valk, Peter
    Kampen, Kim R.
    ter Elst, Arja
    Kaspers, Gertjan
    Cloos, Jacqueline
    Zwaan, C. Michel
    van den Heuvel-Eibrink, Marry M.
    Kamps, Willem A.
    Delwel, Ruud
    Lowenberg, Bob
    de Bont, Eveline S.
    BLOOD, 2009, 114 (22) : 414 - 414
  • [50] Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients
    Marcucci, Guido
    Maharry, Kati S.
    Metzeler, Klaus H.
    Volinia, Stefano
    Wu, Yue-Zhong
    Mrozek, Krzysztof
    Nicolet, Deedra
    Kohlschmidt, Jessica
    Whitman, Susan P.
    Mendler, Jason H.
    Schwind, Sebastian
    Becker, Heiko
    Eisfeld, Ann-Kathrin
    Carroll, Andrew J.
    Powell, Bayard L.
    Kolitz, Jonathan E.
    Garzon, Ramiro
    Caligiuri, Michael A.
    Stone, Richard M.
    Bloomfield, Clara D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (17) : 2086 - 2093